5. Examine the Efficacy of Rifaximin for Hepatic Encephalopathy Patients with Chronic Liver Disease
Muhammad Uthman1, Syed Waseem Ahmad Mujtaba2 and Abdul Matin Qaisar3
Objective: To evaluate the effects and outcomes of rifaximin for the treatment of hepatic encephalopathy with chronic liver disease patients.
Study Design: Prospective/Randomized controlled trial study.
Place and Duration of Study: This study was conducted at the Department of Medicine, Shaikh Zayed Hospital Lahore from 1st July 2019 to 31st December 2019.
Materials and Methods: Eighty four patients of both genders whom were diagnosed with hepatic encephalopathy with chronic liver disease were including in this study. All the patients were divided into two groups, Group A included 42 patients and received treatment rifaximin with lactulose, Group B (control group) included 42 patients receiving placebo with lactulose. Follow-up was taken at 15 days or at discharge. Hepatic encephalopathy index and Child-Turcotte-Pugh (CTP) score and model for end-stage liver disease (MELD) were recorded to examine the outcome of treatment.
Results: In group A 30 patients were males and 12 were females while in Group B, 32 patients were males and 10 patients were females. In Group A, 34 patients were ages <60 years while 8 patients had ages >60 years, In Group B, 33 patients were ages <60 years and 9 patients were ages >60 years. At start of treatment Child-Turcotte-Pugh score p-value 0.467 and model for end-stage liver disease index p-value 0.874 were not statistically significant difference between two groups. Toward the finish of treatment there was noteworthy distinction discovered identified with hepatic encephalopathy file p-esteem 0.039 and model for end-stage liver ailment file p-esteem <0.05 than fake treatment gathering. Youngster Turcotte-Pugh score 0.621 was additionally lower in rifaximin bunch than Group B.
Conclusion: The use of rifaximin with lactulose for the treatment of hepatic encephalopathy resulted better outcome than placebo with respect to model for end-stage liver disease index and hospital stay. Key Word: Rifaximin, Chronic liver disease, Hepatic encephalopathy
Citation of article: Uthman M, Mujtaba SWA, Qaisar AM. Examine the Efficacy of Rifaximin for Hepatic Encephalopathy Patients with Chronic Liver Disease. Med Forum 2020;31(4):19-22